<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Autoimmunity in patients with inborn errors of immunity/primary immunodeficiency</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Autoimmunity in patients with inborn errors of immunity/primary immunodeficiency</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Autoimmunity in patients with inborn errors of immunity/primary immunodeficiency</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Markus G Seidel, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark H Wener, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan S Orange, MD, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H100035049"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with inborn errors of immunity (IEI; formerly called "primary immunodeficiencies" [PIDs]) have dysregulated immune processes, which can result in an increased susceptibility to infectious diseases, autoimmune disorders, autoinflammation, and malignancies. Thus, the term "inborn errors of immunity" was coined to reflect this broader spectrum of potentially deficient immune processes and to encompass all the subgroups of diseases with immune dysregulation or "primary immune regulatory disorders" (PIRD), autoinflammatory syndromes, and tumor predisposition, in addition to those with a predominant deficiency of immunity against infectious microorganisms.</p><p>This topic will discuss the most common manifestations of autoimmunity in patients with IEI and review the autoimmune disorders associated with the most prevalent IEI. Malignancies in patients with IEI are reviewed separately. (See  <a class="medical medical_review" href="/d/html/95906.html" rel="external">"Malignancy in inborn errors of immunity"</a>.)</p><p class="headingAnchor" id="H157785599"><span class="h1">CLASSIFICATION OF IEI</span><span class="headingEndMark"> — </span>IEI are classified into 10 major categories of disorders<em> </em>[<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>I</strong> – Immunodeficiencies affecting cellular and humoral immunity. (See  <a class="medical medical_review" href="/d/html/3935.html" rel="external">"Combined immunodeficiencies: An overview"</a> and  <a class="medical medical_review" href="/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>II</strong> – Combined immunodeficiencies with associated or syndromic features. (See  <a class="medical medical_review" href="/d/html/3951.html" rel="external">"Syndromic immunodeficiencies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>III</strong> – Predominantly antibody deficiencies. (See  <a class="medical medical_review" href="/d/html/3914.html" rel="external">"Primary humoral immunodeficiencies: An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IV</strong> – Diseases of immune dysregulation (including hemophagocytic lymphohistiocytosis syndromes, lymphoproliferative syndromes and susceptibility to Epstein-Barr virus, defects of regulatory T cells, and immune dysregulation syndromes with colitis). (See  <a class="medical medical_review" href="/d/html/87499.html" rel="external">"Clinical features and diagnosis of hemophagocytic lymphohistiocytosis"</a> and  <a class="medical medical_review" href="/d/html/3924.html" rel="external">"IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>V</strong> – Congenital defects of phagocyte number or function. (See  <a class="medical medical_review" href="/d/html/3913.html" rel="external">"Primary disorders of phagocyte number and/or function: An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VI</strong> – Defects in intrinsic and innate immunity. (See  <a class="medical medical_review" href="/d/html/13572.html" rel="external">"An overview of the innate immune system"</a> and  <a class="medical medical_review" href="/d/html/89801.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: An overview"</a> and  <a class="medical medical_review" href="/d/html/13569.html" rel="external">"Chronic mucocutaneous candidiasis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VII</strong> – Autoinflammatory disorders (including periodic fever syndromes, familial cold autoinflammatory syndrome, tumor necrosis factor [TNF] receptor-1 associated periodic syndrome [TRAPS], and others). (See  <a class="medical medical_review" href="/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview"</a> and  <a class="medical medical_review" href="/d/html/5580.html" rel="external">"Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)"</a> and  <a class="medical medical_review" href="/d/html/5585.html" rel="external">"Cryopyrin-associated periodic syndromes and related disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VIII</strong> – Complement deficiencies. (See  <a class="medical medical_review" href="/d/html/3962.html" rel="external">"Inherited disorders of the complement system"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IX</strong> – Bone marrow failure syndromes. (See  <a class="medical medical_review" href="/d/html/109795.html" rel="external">"Clinical manifestations and diagnosis of Fanconi anemia"</a> and  <a class="medical medical_review" href="/d/html/100663.html" rel="external">"Dyskeratosis congenita and other telomere biology disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>X</strong> – Phenocopies of IEI (ie, variations due to a somatic mutation in a gene, autoantibody-mediated destruction of a gene product, or other acquired changes, which mimic a disease caused by an inherited germline mutation of that gene). As an example, an autoantibody to complement factor H can cause atypical hemolytic uremic syndrome (aHUS) with thrombotic microangiopathy (TMA), similar to what is seen in patients with primary factor H deficiency (see  <a class="medical medical_review" href="/d/html/3962.html" rel="external">"Inherited disorders of the complement system"</a>), or a somatic mutation in TNF receptor superfamily member 6 (<em>TNFRSF6</em>) causing nonhereditary autoimmune lymphoproliferative syndrome (ALPS) without a germline mutation in <em>FAS</em>. (See  <a class="medical medical_review" href="/d/html/16361.html" rel="external">"Autoimmune lymphoproliferative syndrome (ALPS): Epidemiology and pathogenesis", section on 'Pathogenesis'</a>.)</p><p></p><p>The classification of IEI is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/117758.html" rel="external">"Inborn errors of immunity (primary immunodeficiencies): Classification"</a>.)</p><p>Autoimmunity may occur in any subgroup of IEI, but it represents a hallmark of the category "diseases with immune dysregulation," or primary immune regulatory disorders (PIRD), which includes category IV above [<a href="#rid1">1</a>]. The phenotypic classification of IEI was published separately [<a href="#rid2">2</a>], and working definitions for the clinical diagnosis of IEI, especially useful in patients whose genetic diagnosis is pending, have been proposed by the European Society of Immunodeficiencies [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H374900279"><span class="h1">MANIFESTATIONS OF AUTOIMMUNITY AND IMMUNE DYSREGULATION IN IEI</span><span class="headingEndMark"> — </span>Autoimmunity is one possible manifestation of deregulated immune function. The defects underlying IEI impact at least three important areas of immune function:</p><p class="bulletIndent1"><span class="glyph">●</span>The ability to fend off and eliminate dangerous exogenous pathogens is impaired, resulting in an increased frequency and severity of common infections, infections with unusual or opportunistic pathogens, or chronic infections (including recurring reactivations) with viruses, some of which may cause malignant transformation directly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The recognition and clearance of altered endogenous cells and cell debris (ie, immune surveillance), deoxyribonucleic acid (DNA) damage repair, or leukocyte maturation and function may be defective, leading to increased susceptibility to autoinflammation and malignancies. Of note, predisposition to malignancy may also arise from the disturbed maturation of an immune cell itself as an intrinsic feature of the IEI, independent of compromised immune surveillance, chronic inflammation, or impaired clearance of viral infections [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/95906.html" rel="external">"Malignancy in inborn errors of immunity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The regulation of immune processes and the induction and maintenance of tolerance to self are compromised, contributing to autoimmunity; chronic (auto)inflammation of the gut and other tissues; rheumatologic manifestations; granuloma formation in parenchymal organs or skin, gut, and other tissues; lymphoproliferation (ie, generalized lymphadenopathy, splenomegaly); focal or diffuse lymphocytic organ infiltration; and/or hemophagocytosis [<a href="#rid5">5-7</a>].</p><p></p><p class="headingAnchor" id="H100035055"><span class="h1">GENERAL PRINCIPLES OF AUTOIMMUNITY IN IEI</span><span class="headingEndMark"> — </span>A wide variety of autoimmune diseases are found in patients with IEI. There is no general tissue or organ restriction, nor is there a sex or age predominance like that seen in autoimmune diseases affecting the general population.</p><p>Autoimmune cytopenias, endocrinopathies, enteropathy, arthritis, hepatitis, glomerulonephritis, lupus-like systemic manifestations, and many other disorders can develop in patients with IEI, and, like other noninfectious manifestations of IEI, autoimmunity can develop at any age and at any stage in the course of the IEI [<a href="#rid8">8,9</a>]. However, among patients with IEI and autoimmunity, there tend to be IEI-typical patterns of organ manifestations and a younger age of onset of autoimmunity in patients with combined immunodeficiencies than in those with B cell deficiencies [<a href="#rid7">7</a>]. The quality of life of a patient with IEI may be severely compromised due to the manifestation of autoimmune diseases and consequent immunosuppressive treatment. In addition, the outcome of patients with IEI is worse if autoimmune manifestations or inflammatory complications exist compared with patients with the same IEI without autoimmunity/inflammation, and preexisting autoimmunity/inflammation adversely affects the outcomes of hematopoietic cell transplantation in IEI patients [<a href="#rid7">7</a>].</p><p>Patients with IEI can develop autoimmunity in the strict sense (ie, specific autoantibody-mediated organ destruction), like that seen in autoimmune cytopenias or autoimmune hepatitis. Alternatively, autoreactive cellular immune mechanisms (due to a lack of self-tolerance) and hyperinflammation (based on positive feedback loops of ineffective immune cells via secreted mediators) may cause self-destruction rather than protection. It is unclear why autoimmunity affects one specific organ in one IEI and another organ in a different IEI [<a href="#rid10">10-15</a>].</p><p class="headingAnchor" id="H374900286"><span class="h2">Selected autoimmune disorders in common forms of IEI</span><span class="headingEndMark"> — </span>Some IEI are associated with specific autoimmune diseases, and an awareness of these patterns allows clinicians to monitor patients more effectively [<a href="#rid15">15,16</a>]. The leading autoimmune organ manifestations of the most prevalent IEI are cytopenias, endocrinopathies, and enteropathies. The table shows the most common IEI and the autoimmune disorders most often encountered in patients with these immunodeficiencies  (<a class="graphic graphic_table graphicRef104453" href="/d/graphic/104453.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H374900316"><span class="h3">Cytopenias</span><span class="headingEndMark"> — </span>The autoimmune cytopenias most often reported in IEI are [<a href="#rid17">17-20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Immune thrombocytopenia (ITP)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune hemolytic anemia (AIHA)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune neutropenia (AIN)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evans syndrome (ie, the combination of Coombs-positive warm AIHA and ITP; less commonly, patients will also have AIN)</p><p></p><p>Besides cellular or antibody-mediated autoimmunity, mechanisms other than autoimmunity may contribute to cytopenias in IEI, including hemophagocytosis, lymphoproliferation (causing splenic sequestration of blood cells), bone marrow failure, and myelosuppressive viruses or toxins [<a href="#rid17">17</a>]. Diseases involving antibodies against hematopoietic cells of the peripheral blood or against precursor cells of the bone marrow represent one of the most frequent autoimmune manifestations in a variety of IEI, including autoimmune lymphoproliferative syndrome (ALPS); common variable immunodeficiency (CVID) without known gene defect or, for example, due to deficiency of nuclear factor kappa B subunit 1 or 2 (NFKB1 or NFKB2); and immunoglobulin A (IgA) deficiency [<a href="#rid1">1,21</a>]. Immune cytopenias are also seen in a wide range of rare<em> </em>combined immunodeficiencies, such as deficiency of recombinase-activating gene 1 or 2 <em>(RAG1 or RAG2)</em>, adenosine deaminase (ADA), purine nucleotide phosphorylase (PNP), serine threonine kinase 4/macrophage-simulating 1 (STK4/MST1), or Ca<sup>2+</sup>-channelopathies, and in DiGeorge (22q11 deletion) syndrome and Wiskott-Aldrich syndrome (WAS), as well as primary immune regulatory disorders (PIRDs) such as the dominant cytotoxic T lymphocyte antigen 4 (CTLA4) haploinsufficiency with autoimmune infiltration (CHAI) immune dysregulation syndrome; immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome; CD25 deficiency; or in patients with gain-of-function mutations in signal transducer and activator of transcription (STAT) 1, STAT3, IKAROS, or suppressor of cytokine signaling 1 (SOCS1) haploinsufficiency [<a href="#rid1">1,2,5,10,11,22-30</a>]. Additionally, immune cytopenias are a typical finding in patients with<em> </em>lipopolysaccharide (LPS) responsive beige-like anchor (LRBA) deficiency [<a href="#rid31">31-35</a>], whereas cytopenias in patients with ADA2 deficiency are mainly due to bone marrow failure [<a href="#rid36">36</a>]. Thus, monogenic IEI should be included in the differential diagnosis of cytopenias, especially of Evans syndrome in children [<a href="#rid17">17,18</a>].</p><p class="headingAnchor" id="H374900323"><span class="h3">Endocrinopathies</span><span class="headingEndMark"> — </span>Autoimmune thyroid diseases or other endocrinopathies, such as type 1 diabetes mellitus and Addison disease, are seen in IEI. Autoimmune endocrinopathies are most prominent in:</p><p class="bulletIndent1"><span class="glyph">●</span>DiGeorge (22q11 deletion) syndrome (see  <a class="medical medical_review" href="/d/html/83396.html" rel="external">"DiGeorge (22q11.2 deletion) syndrome: Clinical features and diagnosis", section on 'Autoimmune disease'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IPEX and IPEX-like disorders [<a href="#rid12">12,37-40</a>] (see  <a class="medical medical_review" href="/d/html/3924.html" rel="external">"IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune polyendocrinopathy with candidiasis and ectodermal dystrophy (APECED) syndromes [<a href="#rid41">41-43</a>] (see  <a class="medical medical_review" href="/d/html/13569.html" rel="external">"Chronic mucocutaneous candidiasis", section on 'Autoimmune regulator deficiency'</a>)</p><p></p><p class="headingAnchor" id="H374900330"><span class="h3">Enteropathies</span><span class="headingEndMark"> — </span>Autoimmune or chronic inflammatory enteropathy is another important manifestation of immune dysregulation, which occurs frequently in IEI patients and can represent both a diagnostic and therapeutic challenge  (<a class="graphic graphic_table graphicRef104453" href="/d/graphic/104453.html" rel="external">table 1</a>). Various clinical and histopathologic entities of gut disease have been described in IEI, including intractable diarrhea (as seen in IPEX and IPEX-like syndromes), celiac disease, colitis, and enteritis with lymphocytic infiltration.</p><p>Inflammatory bowel disease (IBD) and IBD-like diseases are regularly observed in CVID, WAS, chronic granulomatous disease (CGD), IPEX and IPEX-like syndromes, the colitis-linked immune dysregulation syndromes of interleukin (IL) 10 and IL-21 signaling defects [<a href="#rid44">44,45</a>], CTLA4 haploinsufficiency, LRBA deficiency, X-linked inhibitor of apoptosis (XIAP) deficiency (X-linked lymphoproliferative [XLP] disease type 2), nuclear factor of activated T cells 5 (NFAT5) haploinsufficiency, transforming growth factor beta 1 (TGFB1), receptor interacting serine/threonine kinase 1 (RIPK1), or E74-like ETS transcription factor 4 (ELF4) deficiency, as well as in nuclear factor-kappa-B (NFkB) essential modulator (NEMO) deficiency [<a href="#rid1">1,5,22,23,46-52</a>]. Gastrointestinal autoimmune or inflammatory manifestations in IEI occur more frequently in the category of "innate immunodeficiencies" than in T or B cell disorders [<a href="#rid7">7</a>]. They are reviewed in more detail separately. (See  <a class="medical medical_review" href="/d/html/99315.html" rel="external">"Gastrointestinal manifestations in primary immunodeficiency"</a>.)</p><p class="headingAnchor" id="H4200252196"><span class="h1">POSSIBLE PATHOGENIC MECHANISMS</span><span class="headingEndMark"> — </span>There are multiple potential pathways to the development of autoimmune disease and immune dysregulation.</p><p class="headingAnchor" id="H651026370"><span class="h2">Autoimmunity</span><span class="headingEndMark"> — </span>Common autoimmune disorders in the general population, such as rheumatoid arthritis or systemic lupus erythematosus (SLE), are complex polygenic phenotypes in which there may be several concomitant defects in immune function underlying disease pathogenesis. In contrast, monogenic diseases, which sometimes result in defects in a specific immune process or pathway, can provide insight into how immunologic tolerance is normally established and maintained, as well as illustrate the consequences of defective tolerance  (<a class="graphic graphic_table graphicRef104453" href="/d/graphic/104453.html" rel="external">table 1</a>) [<a href="#rid53">53-55</a>].</p><p>One group has categorized some of the known IEI into defects in different overlapping immunologic pathways or processes that underlie autoimmunity [<a href="#rid56">56</a>]. In addition to this oversimplified construct, some monogenic defects impact several pathways simultaneously. Examples of IEI affecting important pathways are provided:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Defects in central T cell tolerance</strong> – Central T cell tolerance results from the deletion of autoreactive T cells during development in the thymus (negative selection). This process involves interaction of developing T cells with thymic stromal cells and requires the product of the autoimmune regulator (<em>AIRE) </em>gene, which is essential for intrathymic presentation of autologous antigens. Mutations in <em>AIRE</em> result in defective presentation of self-antigens in the thymus. More than 70 mutations in <em>AIRE</em> have been identified that result in the disorder autoimmune polyendocrinopathy with candidiasis and ectodermal dystrophy (APECED), which is characterized by autoimmune disease affecting multiple organs and susceptibility to candidiasis  (<a class="graphic graphic_table graphicRef104453" href="/d/graphic/104453.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/13569.html" rel="external">"Chronic mucocutaneous candidiasis", section on 'Autoimmune regulator deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Defects in B cell function and tolerance</strong> – In B cell development, central tolerance is achieved by receptor-editing in the bone marrow, which removes naïve B cells expressing self-reactive antibodies. In some patients with common variable immunodeficiency (CVID), mutations in tumor necrosis factor receptor superfamily member 13B (<em>TNFRSF13B</em>) lead to defects in <strong>t</strong>ransmembrane <strong>a</strong>ctivator and <strong>c</strong>alcium-modulator and cyclophilin ligand (CAML) <strong>i</strong>nteractor (TACI), a molecule that is important in class-switch recombination, as well as in plasma cell differentiation and antibody production. Patients have increases in autoreactive B cells, autoimmunity, and autoimmune cytopenias. (See  <a class="medical medical_review" href="/d/html/3904.html" rel="external">"Pathogenesis of common variable immunodeficiency"</a>.)</p><p></p><p class="bulletIndent1">Hyperimmunoglobulin M (HIGM) syndrome can result from multiple defects, one of which is deficiency in activation-induced cytidine deaminase (AID), a ribonucleic acid (RNA) editing enzyme important in immunoglobulin class-switch recombination and somatic hypermutation. Patients with AID deficiency classically present with normal or elevated immunoglobulin M (IgM) and low immunoglobulin G (IgG) and IgA, lymphadenopathy with enlarged germinal centers, and recurrent bacterial infections. A subset develops autoimmune cytopenias, Crohn disease, or SLE. (See  <a class="medical medical_review" href="/d/html/13567.html" rel="external">"Hyperimmunoglobulin M syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Defects in peripheral tolerance</strong> – Peripheral tolerance refers to mechanisms that inactivate or remove mature T and B cells that recognize and could potentially react to self-antigens, including apoptosis, anergy, and suppression by T regulatory cells (Tregs). Immune checkpoint defects like cytotoxic T lymphocyte antigen 4 (CTLA4) insufficiency, lipopolysaccharide (LPS) responsive beige-like anchor (LRBA) deficiency, or DEF6 guanine nucleotide exchange factor (DEF6) deficiency predominantly act through impaired Treg function. Foxp3 is a member of the forkhead box P family of transcription factors and is fundamental to the function of Tregs. Its gene is located on the X chromosome, and, when defective, male infants develop autoimmune enteropathy, endocrinopathy, and severe eczematous dermatitis. (See  <a class="medical medical_review" href="/d/html/3924.html" rel="external">"IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Defects in VDJ recombination</strong> – Variable, diversity, and joining (VDJ) recombination is critical in immunoglobulin and T cell receptor function and maturation (see  <a class="medical medical_review" href="/d/html/3977.html" rel="external">"Immunoglobulin genetics"</a>). The products of recombinase-activating genes 1 and 2 (<em>RAG1</em> and <em>RAG2</em>) mediate the creation of double-stranded DNA breaks at the sites of recombination and signal sequences during T and B cell receptor gene rearrangement. When severely defective, a T cell-negative, B cell-negative, natural killer cell-positive severe combined immunodeficiency (T-B-NK+ SCID) results, while hypomorphic defects lead to T and B cells that survive but are oligoclonal and often self-reactive. Hypomorphic <em>RAG</em> mutations have been detected in multiple IEI, including Omenn syndrome, idiopathic CD4 lymphocytopenia, and specific antibody deficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Defects in apoptosis</strong> – During lymphocytic differentiation, maturation, and selection processes, apoptosis plays an important regulatory role. Once activated, an immune response must also be downregulated when the threat to the host has been neutralized. Defects in apoptosis pathways lead to uncontrolled lymphoproliferation, with lymphadenopathy, hepatosplenomegaly, autoimmune organ damage, cytopenias, and increased risk of lymphoma. Autoimmune lymphoproliferative syndrome (ALPS) presents in young children, usually as some combination of lymphadenopathy/splenomegaly/hepatomegaly, autoimmune disease (cytopenias), and lymphoma. Flow cytometry shows elevated numbers of T cells in peripheral blood and tissue specimens that express the alpha/beta T cell receptor but lack both CD4 and CD8 (alpha/beta double-negative T cells), elevated levels of interleukin (IL) 10 in blood, increased levels of vitamin B12, and defective Fas-mediated apoptosis in vitro. Multiple autoantibodies are characteristic. (See  <a class="medical medical_review" href="/d/html/16837.html" rel="external">"Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperactivation of lymphocytes</strong> – Defects in molecules in the activation pathways of T and B cells may result in hyperactivation, immune dysregulation, and lymphoproliferation. Specific disorders include activating mutations in phosphoinositide 3-kinase (PI3K), deletions in the autoinhibitory domain of phospholipase C-gamma-2 (PLC-gamma-2), and protein kinase C-delta deficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased activation of type 1 interferon pathways</strong> – Type 1 interferons (IFN-alpha and IFN-beta), when given therapeutically, can promote autoimmunity. The causative mechanisms of this adverse effect are not fully understood but include inhibition of Tregs, enhanced major histocompatibility complex (MHC) class II antigen expression with subsequent activation of T helper lymphocytes by autoantigens, and induction of proinflammatory cytokines.</p><p></p><p class="bulletIndent1">Monogenic defects that result in increased production of type 1 interferons include gain-of-function mutations in signal transducer and activator of transcription (STAT) 1, a signaling protein in the pathway initiated by binding of IFN-alpha or IFN-beta to its receptor. Patients present with chronic mucocutaneous candidiasis and an array of autoimmune disorders. (See  <a class="medical medical_review" href="/d/html/13569.html" rel="external">"Chronic mucocutaneous candidiasis", section on 'Signal transducer and activator of transcription (STAT1) dysfunction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Defects in early complement components</strong> – Defects in the early complement components (ie, C1q, C1r/s, C2, and C4) are all associated with a greatly increased risk of developing SLE. Some patients have increased susceptibility to infection as well. These complement proteins function as acute-phase reactants and are important for opsonization of immune complexes and apoptotic cells. In patients with a deficiency, self-antigens are more likely to induce autoimmunity. (See  <a class="medical medical_review" href="/d/html/3962.html" rel="external">"Inherited disorders of the complement system", section on 'Specific disorders'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Defective removal of cell debris</strong> – Similar to defects in early complement components, defects in phagocyte Fc receptors (Fc-gamma-RII and Fc-gamma-RIII), variants in C-reactive protein (CRP), and defects in the receptor for C3bi on monocytes all impair normal removal of cell debris and apoptotic cells by phagocytes. These defects have been identified in some patients with SLE [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/d/html/13572.html" rel="external">"An overview of the innate immune system", section on 'Homeostasis in the innate immune system'</a>.)</p><p></p><p>A discussion of the known mechanisms of more common autoimmune diseases is found separately. (See  <a class="medical medical_review" href="/d/html/5579.html" rel="external">"Overview of autoimmunity", section on 'Pathogenetic mechanisms'</a> and  <a class="medical medical_review" href="/d/html/13933.html" rel="external">"Normal B and T lymphocyte development"</a>.)</p><p class="headingAnchor" id="H3987569530"><span class="h2">Immune dysregulation</span><span class="headingEndMark"> — </span>Some manifestations of immune dysregulation in IEI may arise from uncontrolled processes in multiple components of the immune system and comprise a special form of autoimmunity in a wider sense [<a href="#rid5">5</a>]. Examples include inflammatory bowel disease (IBD), granuloma formation, lymphoproliferation, and hemophagocytosis. A similar, unspecific process of immune dysregulation may be triggered in diseases categorized under "autoinflammatory disorders" (category VII from the IEI classification) [<a href="#rid1">1,2</a>], some of which may present with autoimmunity, thrombocytopenia, hemolytic anemia, severe enterocolitis, vasculitis, etc. (See  <a class="medical medical_review" href="/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview"</a>.)</p><p>Chronic IBD/enteropathy is a typical example of immune dysregulation in IEI [<a href="#rid57">57</a>]. Specifically, colitis may be observed as a consequence of immune dysregulation in disorders with defective IL-10 and IL-21 signaling [<a href="#rid44">44,45</a>]. In the colitis associated with chronic granulomatous disease (CGD), the impaired ability of neutrophils to digest phagocytosed material results in secretion of proinflammatory cytokines and the attraction and activation of ever more incompetent leukocytes, causing granulomata to form [<a href="#rid46">46</a>]. In immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, autoantibodies against various gut antigens are thought to be involved, in addition to the lack of direct T cell suppression by Tregs. An imbalance of pro- and anti-inflammatory monocytes/macrophages contributes to the pathology in other IEI. For instance, a gain-of-function mutation in NLR family CARD domain-containing 4 (<em>NLRC4</em>) may cause macrophage activation and inflammation due to defective inflammasome regulation, whereas, in XIAP deficiency, X-linked lymphoproliferative (XLP) disease type 2 and very-early-onset IBD are mediated by nucleotide-binding oligomerization domain (NOD) signaling defects and an increased susceptibility to cell death [<a href="#rid58">58</a>]. Apoptosis defects also play a role in colitis seen in deficiency of receptor interacting serine/threonine kinase 1 (RIPK1) [<a href="#rid51">51,52</a>] or caspase 8 (CASP8) [<a href="#rid59">59</a>].</p><p>Lymphoproliferation (generalized lymphadenopathy, splenomegaly), another possible manifestation of immune dysregulation, can also result from multiple mechanisms. It is pathognomonic in ALPS but also a common symptom in CD27 or CD70 deficiency, IL-2-inducible kinase (ITK) deficiency, XLP type 1, and CVID [<a href="#rid11">11,22,60-66</a>]. Lymphoproliferation and lymphoma (Hodgkin and non-Hodgkin lymphoma) are often Epstein-Barr virus (EBV) associated. Of note, lymphadenopathy and splenomegaly may also be triggered by unspecified infections (not only EBV) in CVID and in almost any other IEI and are not always primarily attributable to immune dysregulation  (<a class="graphic graphic_table graphicRef69397" href="/d/graphic/69397.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef115359" href="/d/graphic/115359.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/3904.html" rel="external">"Pathogenesis of common variable immunodeficiency", section on 'Genetics'</a>.)</p><p>Primary or familial hemophagocytic lymphohistiocytosis syndromes also belong to the group of disorders with immune dysregulation (category IV of the IEI classification) and are usually caused by genes involved in cellular cytotoxicity pathways of cytotoxic T effector and NK cells [<a href="#rid1">1,67</a>]. Secondary hemophagocytic syndrome, lymphoproliferation, and lymphoma in the context of IEI may be infection triggered (most often EBV or another DNA virus) and characteristically occur in T-B cell communication defects like XLP and CD27/CD70 deficiency [<a href="#rid64">64,65,68-70</a>]. However, other mechanisms of malignant transformation, like the underlying lymphocyte maturation defect, may also contribute to the development of lymphoma in this group of IEI [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/87499.html" rel="external">"Clinical features and diagnosis of hemophagocytic lymphohistiocytosis"</a> and  <a class="medical medical_review" href="/d/html/95906.html" rel="external">"Malignancy in inborn errors of immunity"</a>.)</p><p class="headingAnchor" id="H369701297"><span class="h1">WHEN TO SUSPECT AN UNDERLYING IEI</span><span class="headingEndMark"> — </span>When signs/symptoms of autoimmunity develop before the patient has experienced recurrent infections, an underlying IEI may be missed and its diagnosis delayed for years. However, if an underlying IEI can be recognized in a timely manner, future infections or additional organ involvement may be prevented by early initiation of proper treatment and implementation of prophylactic measures [<a href="#rid8">8</a>].</p><p>Two clinical clues that a patient with autoimmunity may have an underlying IEI are:</p><p class="bulletIndent1"><span class="glyph">●</span>The development of an autoimmune disorder at an age that is younger than usual.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The development of autoimmune processes affecting multiple organ systems, not necessarily at the same time, that cannot be unified under a single rheumatologic diagnosis.</p><p></p><p>Some patients with IEI demonstrate both of these patterns [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H369701317"><span class="h2">Early-onset autoimmunity</span><span class="headingEndMark"> — </span>Autoimmune disorders developing in patients who are younger than usual should alert the clinician to the possibility of an underlying IEI [<a href="#rid5">5,8</a>]. As an example, infants with immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome often present with intractable diarrhea and failure to thrive, with signs and symptoms of allergic inflammation affecting multiple systems (eg, eczema, food allergy, eosinophilia, elevated total and antigen-specific immunoglobulin E [IgE]) within the first year of life. Severe forms of IPEX may develop neonatal type 1 diabetes mellitus, and many patients also develop thyroiditis. Other examples would be severe early-onset inflammatory bowel disease (IBD; ie, at toddler age) due to a mutation in one of the early-onset/very-early-onset IBD genes [<a href="#rid59">59</a>] or a lupus-like autoimmunity syndrome before adolescence (eg, in deficiency of protein kinase C delta [PRKCD]) [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/d/html/3924.html" rel="external">"IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked"</a>.)</p><p class="headingAnchor" id="H369701349"><span class="h2">Multiorgan involvement</span><span class="headingEndMark"> — </span>The occurrence of autoimmune involvement of multiple organs (often at different times in the patient's life) in the absence of a unifying rheumatologic diagnosis is another pattern suggestive of the presence of an underlying IEI. The following are examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a report of a family affected by the rare IEI, lipopolysaccharide (LPS) responsive beige-like anchor (LRBA) deficiency, one child presented at the age of two years with immune thrombocytopenia (ITP) and generalized lymphoproliferative disease [<a href="#rid72">72</a>]. ITP became chronic and progressed to autoimmune pancytopenia. Generalized lymphadenopathy prompted a lymph node biopsy, which revealed findings consistent with autoimmune lymphoproliferative syndrome (ALPS). Her sister presented with autoimmune hemolytic anemia (AIHA) at five years of age, followed by chronic enteropathy with severe malabsorption and vasculitis, as well as recurring urinary and respiratory tract infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with common variable immunodeficiency (CVID) may present with AIHA, ITP, or both (Evans syndrome) in childhood or adolescence and later develop frequent or recurrent sinopulmonary and respiratory tract infections, at which point the underlying immunodeficiency is often detected. Disorders that are common in CVID and may present at any point in the patient's life include IBD, granulomatous-lymphocytic interstitial lung disease (GLILD), thyroiditis, and a seronegative inflammatory arthritis. (See  <a class="medical medical_review" href="/d/html/3928.html" rel="external">"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults"</a>.)</p><p></p><p class="headingAnchor" id="H1753021952"><span class="h1">WHEN TO REFER</span><span class="headingEndMark"> — </span>Patients with IEI may be under the care of generalists or specialists in allergy/immunology, hematology, infectious diseases, rheumatology, oncology, or gastroenterology depending on the type of disorder that has necessitated medical care. It is not uncommon for the diagnosis of an underlying IEI to be delayed for years until someone recognizes that the combination of disorders afflicting the patient might be unified under the diagnosis of IEI.</p><p>When a patient's presentation or clinical course raises the possibility of an underlying IEI, initial testing can be performed by the generalist. The evaluation is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/3903.html" rel="external">"Laboratory evaluation of the immune system"</a> and  <a class="medical medical_review" href="/d/html/3948.html" rel="external">"Inborn errors of immunity (primary immunodeficiencies): Overview of management"</a>.)</p><p>Of note, the laboratory parameters analyzed for the diagnosis of autoimmunity, such as autoantibodies and inflammation markers, may be nonspecific and similar between patients with or without underlying IEI.</p><p>Definitive diagnosis of an IEI usually requires the input of a specialist since more advanced immunologic tests require varying degrees of expertise to perform and interpret, may not be widely available, and are often costly. In addition, knowledge about the possible diagnoses in question is invaluable in deciding the type of testing to pursue first. Depending on the setting, clinicians with expertise in immunology are most often trained in allergy/immunology, infectious diseases, rheumatology, or pediatric hematology/oncology.</p><p class="headingAnchor" id="H100035067"><span class="h1">MONITORING FOR AUTOIMMUNITY</span><span class="headingEndMark"> — </span>It is helpful to understand the associations between specific IEI and autoimmune disorders  (<a class="graphic graphic_table graphicRef104453" href="/d/graphic/104453.html" rel="external">table 1</a>). Monitoring for these diseases can be accomplished with a periodic review of systems for which clinical scores of IEI with immune dysregulation may be useful [<a href="#rid16">16</a>]. In some cases, the patient can be educated about the most common signs of the most dangerous autoimmune conditions. If a new sign or symptom consistent with autoimmunity or immune dysregulation emerges, cooperation with the respective subspecialties, such as hematology, endocrinology, gastroenterology, and infectious diseases, should occur without delay.</p><p class="headingAnchor" id="H127903"><span class="h2">Considering alternative etiologies</span><span class="headingEndMark"> — </span>When assessing a patient with IEI for possible autoimmunity, it is important to begin with a broad differential diagnosis since infectious diseases, adverse effects of medications, and malignancies can mimic autoimmune processes:</p><p class="bulletIndent1"><span class="glyph">●</span>Viral and other infections may lead to myelosuppression and (pan)cytopenia, enterocolitis, or generalized lymphadenopathy and hepatosplenomegaly [<a href="#rid17">17</a>]. Mycobacterial infections may lead to granuloma formation. DNA viruses, norovirus, and <em>Campylobacter</em> and <em>Salmonella </em>(in some IEI) are typical microorganisms that may cause acute or chronic infection with cytopenia, enteropathy, or hepatitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Certain drugs given to patients with IEI are myelotoxic or hepatotoxic and may lead to a clinical picture of cytopenia or hepatitis (eg, antibiotics, antiviral drugs, antiseizure medications, antipyretics, or immunosuppressants).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignancies, especially lymphomas, can be misinterpreted as "normal (polyclonal)" lymphoproliferation. In the setting of rapidly evolving or persistent lymphadenopathy/lymphoproliferation, a patient should be referred to a hematology/oncology specialist. A histopathologic assessment of lymph node and/or bone marrow tissue, including analyses of clonality and Epstein-Barr virus (EBV) integration, might be required to confirm or exclude lymphoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conversely, absence of typical autoantibodies in a patient with a specific phenotype of an autoimmune disease might prompt searching for a monogenic IEI that might mimic the autoimmune disease, such as autoantibody-negative polyarteritis nodosa and other forms of vasculitis in patients with adenosine deaminase 2 (ADA2) deficiency or alveolar proteinosis (more commonly associated with anti-granulocyte macrophage colony-stimulating factor [GM-CSF] antibodies) in patients with GATA-binding protein 2 (GATA2) deficiency.</p><p></p><p class="headingAnchor" id="H127909"><span class="h1">THERAPIES</span><span class="headingEndMark"> — </span>Most autoimmune diseases in patients with an IEI are managed with the same therapies that are used in patients without IEI. In many of these cases, the treatment required to control the autoimmune process may cause secondary immunodeficiency and further increase the risk of infection or malignancy. However, untreated autoimmune disease or chronic tissue damage due to uncontrolled inflammation may cause even equal or greater harm. Cross-specialty cooperation is invaluable when such therapies are required.</p><p>Some treatments seem overtly counterintuitive, such as the use of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> to eliminate autoreactive B cells in a patient with an underlying antibody deficiency. One example is the use of rituximab to control autoimmune hemolytic anemia (AIHA) in patients with common variable immunodeficiency (CVID). Another example is the use of T cell immunosuppression in a patient with a combined immunodeficiency. When such therapies are required, it is helpful to ensure that the patient understands the treatment strategy and is informed about specific risks and complications of the medications that are to be used.</p><p class="headingAnchor" id="H3638703"><span class="h2">Targeted therapies</span><span class="headingEndMark"> — </span>With the advent of next-generation sequencing tools as part of the routine clinical diagnostic repertoire, a genetic diagnosis can be made in more and more IEI patients over time. Aligning the clinical phenotype with a defined signaling pathway often enables the identification and use of a drug that specifically targets the impaired pathway [<a href="#rid73">73</a>]. This is especially valuable in IEI patients with immune dysregulation as broader additional immunosuppression may be avoided by using a specific drug. As an example, <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">abatacept</a>, a soluble cytotoxic T lymphocyte antigen 4 (CTLA4) immunoglobulin, can ameliorate the phenotype of patients with insufficiency of CTLA4 or deficiency of lipopolysaccharide (LPS) responsive beige-like anchor (LRBA) by (partially) restoring regulatory T cell function [<a href="#rid32">32,74</a>].</p><p class="headingAnchor" id="H1486662415"><span class="h2">Transplantation and gene therapy</span><span class="headingEndMark"> — </span>Ultimately, allogeneic hematopoietic cell transplantation may be curative in certain severe monogenetic IEI with autoimmunity if no targeted therapies are available (as is still the case in most IEI) [<a href="#rid75">75,76</a>]. In the future, gene therapy may represent another approach to cure an increasing number of these disorders [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H432672738"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune dysregulation has several presentations</strong> – Dysregulation of immune processes in inborn errors in immunity (IEI) can lead to classic autoimmune disorders, chronic inflammation of the gut and other tissues, granuloma formation, lymphoproliferation and focal or diffuse lymphocytic organ infiltration, and/or hemophagocytosis. (See <a class="local">'Manifestations of autoimmunity and immune dysregulation in IEI'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to suspect an IEI in a patient with autoimmunity</strong> – A wide variety of autoimmune diseases are found in patients with IEI. There is no general tissue or organ restriction, nor is there a sex or age predominance like that seen in autoimmune diseases affecting the general population<em>. </em>Two important clinical clues that an underlying IEI may be present are the development of an autoimmune disorder at an unusually early age and the presence of autoimmune processes that affect multiple organ systems and cannot be unified under a single (eg, rheumatologic) diagnosis.<em> </em>(See <a class="local">'General principles of autoimmunity in IEI'</a> above and <a class="local">'When to suspect an underlying IEI'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Most common autoimmune manifestations in IEI</strong> – The leading autoimmune organ manifestations of the most prevalent IEI are cytopenias, endocrinopathies, and enteropathies. The table shows the most common IEI and the autoimmune disorders most often encountered in patients with these immunodeficiencies  (<a class="graphic graphic_table graphicRef104453" href="/d/graphic/104453.html" rel="external">table 1</a>). (See <a class="local">'Selected autoimmune disorders in common forms of IEI'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenic mechanisms</strong> – Autoimmunity and immune dysregulation can arise from defects in many different immunologic processes in the general population. Most common autoimmune disorders, such as rheumatoid arthritis or systemic lupus erythematosus (SLE), are complex polygenic phenotypes. In contrast, monogenic diseases, which often affect a specific immune process or pathway, can provide insight into how immunologic tolerance is normally established and maintained, as well as illustrate the consequences of defective tolerance. (See <a class="local">'Possible pathogenic mechanisms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific disease associations</strong> – Awareness of associations between specific IEI and autoimmune disorders is helpful in monitoring patients  (<a class="graphic graphic_table graphicRef104453" href="/d/graphic/104453.html" rel="external">table 1</a>). If a new sign or symptom consistent with autoimmunity or immune dysregulation emerges, cooperation with the respective subspecialties, such as hematology, endocrinology, gastroenterology, and infectious diseases, should occur without delay. (See <a class="local">'Monitoring for autoimmunity'</a> above and <a class="local">'When to refer'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Most autoimmune diseases in patients with IEI are managed with the same therapies used in patients without IEI. In some cases, targeted drugs are available that may partially restore the impaired signaling pathway without causing deleterious immunosuppression. In other cases, the treatment required to control the autoimmune process may cause secondary immunodeficiency and further increase the risk of infection or malignancy. In such situations, cross-specialty cooperation is critical. (See <a class="local">'Therapies'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tangye SG, Al-Herz W, Bousfiha A, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2022; 42:1473.</a></li><li><a class="nounderline abstract_t">Bousfiha A, Jeddane L, Picard C, et al. Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. J Clin Immunol 2020; 40:66.</a></li><li><a class="nounderline abstract_t">Seidel MG, Kindle G, Gathmann B, et al. The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. J Allergy Clin Immunol Pract 2019; 7:1763.</a></li><li><a class="nounderline abstract_t">Hauck F, Voss R, Urban C, Seidel MG. Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders. J Allergy Clin Immunol 2018; 141:59.</a></li><li><a class="nounderline abstract_t">Carneiro-Sampaio M, Coutinho A. Early-onset autoimmune disease as a manifestation of primary immunodeficiency. Front Immunol 2015; 6:185.</a></li><li><a class="nounderline abstract_t">Farmand S, Baumann U, von Bernuth H, et al. [Interdisciplinary AWMF guideline for the diagnostics of primary immunodeficiency]. Klin Padiatr 2011; 223:378.</a></li><li><a class="nounderline abstract_t">Fischer A, Provot J, Jais JP, et al. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. J Allergy Clin Immunol 2017; 140:1388.</a></li><li><a class="nounderline abstract_t">Thalhammer J, Kindle G, Nieters A, et al. Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations. J Allergy Clin Immunol 2021; 148:1332.</a></li><li><a class="nounderline abstract_t">Azizi G, Tavakol M, Yazdani R, et al. Autoimmune manifestations among 461 patients with monogenic inborn errors of immunity. Pediatr Allergy Immunol 2021; 32:1335.</a></li><li><a class="nounderline abstract_t">Feske S. Immunodeficiency due to defects in store-operated calcium entry. Ann N Y Acad Sci 2011; 1238:74.</a></li><li><a class="nounderline abstract_t">Price S, Shaw PA, Seitz A, et al. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood 2014; 123:1989.</a></li><li><a class="nounderline abstract_t">Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: a model of immune dysregulation. Curr Opin Allergy Clin Immunol 2002; 2:481.</a></li><li><a class="nounderline abstract_t">Bacchetta R, Gambineri E, Roncarolo MG. Role of regulatory T cells and FOXP3 in human diseases. J Allergy Clin Immunol 2007; 120:227.</a></li><li><a class="nounderline abstract_t">Wildin RS, Freitas A. IPEX and FOXP3: clinical and research perspectives. J Autoimmun 2005; 25 Suppl:56.</a></li><li><a class="nounderline abstract_t">Mauracher AA, Gujer E, Bachmann LM, et al. Patterns of Immune Dysregulation in Primary Immunodeficiencies: A Systematic Review. J Allergy Clin Immunol Pract 2021; 9:792.</a></li><li><a class="nounderline abstract_t">Seidel MG, Tesch VK, Yang L, et al. The Immune Deficiency and Dysregulation Activity (IDDA2.1 'Kaleidoscope') Score and Other Clinical Measures in Inborn Errors of Immunity. J Clin Immunol 2022; 42:484.</a></li><li><a class="nounderline abstract_t">Seidel MG. Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. Blood 2014; 124:2337.</a></li><li><a class="nounderline abstract_t">Hadjadj J, Aladjidi N, Fernandes H, et al. Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes. Blood 2019; 134:9.</a></li><li><a class="nounderline abstract_t">Schiavo E, Martini B, Attardi E, et al. Autoimmune Cytopenias and Dysregulated Immunophenotype Act as Warning Signs of Inborn Errors of Immunity: Results From a Prospective Study. Front Immunol 2021; 12:790455.</a></li><li><a class="nounderline abstract_t">Westermann-Clark E, Meehan CA, Meyer AK, et al. Primary Immunodeficiency in Children With Autoimmune Cytopenias: Retrospective 154-Patient Cohort. Front Immunol 2021; 12:649182.</a></li><li><a class="nounderline abstract_t">Lorenzini T, Fliegauf M, Klammer N, et al. Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations. J Allergy Clin Immunol 2020; 146:901.</a></li><li><a class="nounderline abstract_t">Cunningham-Rundles C. The many faces of common variable immunodeficiency. Hematology Am Soc Hematol Educ Program 2012; 2012:301.</a></li><li><a class="nounderline abstract_t">Buchbinder D, Nugent DJ, Fillipovich AH. Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments. Appl Clin Genet 2014; 7:55.</a></li><li><a class="nounderline abstract_t">Gennery AR. Immunological aspects of 22q11.2 deletion syndrome. Cell Mol Life Sci 2012; 69:17.</a></li><li><a class="nounderline abstract_t">Schubert D, Bode C, Kenefeck R, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 2014; 20:1410.</a></li><li><a class="nounderline abstract_t">Kuehn HS, Ouyang W, Lo B, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 2014; 345:1623.</a></li><li><a class="nounderline abstract_t">Toubiana J, Okada S, Hiller J, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood 2016; 127:3154.</a></li><li><a class="nounderline abstract_t">Olbrich P, Freeman AF. STAT1 and STAT3 mutations: important lessons for clinical immunologists. Expert Rev Clin Immunol 2018; 14:1029.</a></li><li><a class="nounderline abstract_t">Milner JD, Vogel TP, Forbes L, et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 2015; 125:591.</a></li><li><a class="nounderline abstract_t">Haapaniemi EM, Kaustio M, Rajala HL, et al. Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. Blood 2015; 125:639.</a></li><li><a class="nounderline abstract_t">Lopez-Herrera G, Tampella G, Pan-Hammarström Q, et al. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet 2012; 90:986.</a></li><li><a class="nounderline abstract_t">Lo B, Zhang K, Lu W, et al. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 2015; 349:436.</a></li><li><a class="nounderline abstract_t">Gámez-Díaz L, August D, Stepensky P, et al. The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency. J Allergy Clin Immunol 2016; 137:223.</a></li><li><a class="nounderline abstract_t">Habibi S, Zaki-Dizaji M, Rafiemanesh H, et al. Clinical, Immunologic, and Molecular Spectrum of Patients with LPS-Responsive Beige-Like Anchor Protein Deficiency: A Systematic Review. J Allergy Clin Immunol Pract 2019; 7:2379.</a></li><li><a class="nounderline abstract_t">Tesch VK, Abolhassani H, Shadur B, et al. Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score. J Allergy Clin Immunol 2020; 145:1452.</a></li><li><a class="nounderline abstract_t">Lee PY, Kellner ES, Huang Y, et al. Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2). J Allergy Clin Immunol 2020; 145:1664.</a></li><li><a class="nounderline abstract_t">Verbsky JW, Chatila TA. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an evolving web of heritable autoimmune diseases. Curr Opin Pediatr 2013; 25:708.</a></li><li><a class="nounderline abstract_t">Wildin RS, Smyk-Pearson S, Filipovich AH. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2002; 39:537.</a></li><li><a class="nounderline abstract_t">Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057.</a></li><li><a class="nounderline abstract_t">Barzaghi F, Amaya Hernandez LC, Neven B, et al. Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. J Allergy Clin Immunol 2018; 141:1036.</a></li><li><a class="nounderline abstract_t">De Martino L, Capalbo D, Improda N, et al. APECED: A Paradigm of Complex Interactions between Genetic Background and Susceptibility Factors. Front Immunol 2013; 4:331.</a></li><li><a class="nounderline abstract_t">Ahonen P. Autoimmune polyendocrinopathy--candidosis--ectodermal dystrophy (APECED): autosomal recessive inheritance. Clin Genet 1985; 27:535.</a></li><li><a class="nounderline abstract_t">Kisand K, Peterson P. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. J Clin Immunol 2015; 35:463.</a></li><li><a class="nounderline abstract_t">Kotlarz D, Beier R, Murugan D, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 2012; 143:347.</a></li><li><a class="nounderline abstract_t">Salzer E, Kansu A, Sic H, et al. Early-onset inflammatory bowel disease and common variable immunodeficiency-like disease caused by IL-21 deficiency. J Allergy Clin Immunol 2014; 133:1651.</a></li><li class="breakAll">Leiding JW, Holland SM. Chronic granulomatous disease. In: GeneReviews, Pagon RA, Adam MP, Ardinger HH, et al (Eds), University of Washington, Seattle 2012.</li><li><a class="nounderline abstract_t">Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008; 112:277.</a></li><li><a class="nounderline abstract_t">Pachlopnik Schmid J, Canioni D, Moshous D, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 2011; 117:1522.</a></li><li><a class="nounderline abstract_t">Guerrerio AL, Frischmeyer-Guerrerio PA, Lederman HM, Oliva-Hemker M. Recognizing gastrointestinal and hepatic manifestations of primary immunodeficiency diseases. J Pediatr Gastroenterol Nutr 2010; 51:548.</a></li><li><a class="nounderline abstract_t">Huppmann AR, Leiding JW, Hsu AP, et al. Pathologic Findings in NEMO Deficiency: A Surgical and Autopsy Survey. Pediatr Dev Pathol 2015; 18:387.</a></li><li><a class="nounderline abstract_t">Li Y, Führer M, Bahrami E, et al. Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases. Proc Natl Acad Sci U S A 2019; 116:970.</a></li><li><a class="nounderline abstract_t">Cuchet-Lourenço D, Eletto D, Wu C, et al. Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation. Science 2018; 361:810.</a></li><li><a class="nounderline abstract_t">Todoric K, Koontz JB, Mattox D, Tarrant TK. Autoimmunity in immunodeficiency. Curr Allergy Asthma Rep 2013; 13:361.</a></li><li><a class="nounderline abstract_t">Arkwright PD, Abinun M, Cant AJ. Autoimmunity in human primary immunodeficiency diseases. Blood 2002; 99:2694.</a></li><li><a class="nounderline abstract_t">Saifi M, Wysocki CA. Autoimmune Disease in Primary Immunodeficiency: At the Crossroads of Anti-Infective Immunity and Self-Tolerance. Immunol Allergy Clin North Am 2015; 35:731.</a></li><li><a class="nounderline abstract_t">Grimbacher B, Warnatz K, Yong PF, et al. The crossroads of autoimmunity and immunodeficiency: Lessons from polygenic traits and monogenic defects. J Allergy Clin Immunol 2016; 137:3.</a></li><li><a class="nounderline abstract_t">Kelsen JR, Sullivan KE. Inflammatory Bowel Disease in Primary Immunodeficiencies. Curr Allergy Asthma Rep 2017; 17:57.</a></li><li><a class="nounderline abstract_t">Chirieleison SM, Marsh RA, Kumar P, et al. Nucleotide-binding oligomerization domain (NOD) signaling defects and cell death susceptibility cannot be uncoupled in X-linked inhibitor of apoptosis (XIAP)-driven inflammatory disease. J Biol Chem 2017; 292:9666.</a></li><li><a class="nounderline abstract_t">Ouahed J, Spencer E, Kotlarz D, et al. Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies. Inflamm Bowel Dis 2020; 26:820.</a></li><li><a class="nounderline abstract_t">Alkhairy OK, Perez-Becker R, Driessen GJ, et al. Novel mutations in TNFRSF7/CD27: Clinical, immunologic, and genetic characterization of human CD27 deficiency. J Allergy Clin Immunol 2015; 136:703.</a></li><li><a class="nounderline abstract_t">Ghosh S, Bienemann K, Boztug K, Borkhardt A. Interleukin-2-inducible T-cell kinase (ITK) deficiency - clinical and molecular aspects. J Clin Immunol 2014; 34:892.</a></li><li><a class="nounderline abstract_t">Salzer U, Warnatz K, Peter HH. Common variable immunodeficiency: an update. Arthritis Res Ther 2012; 14:223.</a></li><li><a class="nounderline abstract_t">Rensing-Ehl A, Warnatz K, Fuchs S, et al. Clinical and immunological overlap between autoimmune lymphoproliferative syndrome and common variable immunodeficiency. Clin Immunol 2010; 137:357.</a></li><li><a class="nounderline abstract_t">Izawa K, Martin E, Soudais C, et al. Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection. J Exp Med 2017; 214:73.</a></li><li><a class="nounderline abstract_t">Abolhassani H, Edwards ES, Ikinciogullari A, et al. Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency. J Exp Med 2017; 214:91.</a></li><li><a class="nounderline abstract_t">Caorsi R, Rusmini M, Volpi S, et al. CD70 Deficiency due to a Novel Mutation in a Patient with Severe Chronic EBV Infection Presenting As a Periodic Fever. Front Immunol 2017; 8:2015.</a></li><li><a class="nounderline abstract_t">Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med 2012; 63:233.</a></li><li><a class="nounderline abstract_t">Veillette A, Pérez-Quintero LA, Latour S. X-linked lymphoproliferative syndromes and related autosomal recessive disorders. Curr Opin Allergy Clin Immunol 2013; 13:614.</a></li><li><a class="nounderline abstract_t">Salzer E, Daschkey S, Choo S, et al. Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27. Haematologica 2013; 98:473.</a></li><li><a class="nounderline abstract_t">van Montfrans JM, Hoepelman AI, Otto S, et al. CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia. J Allergy Clin Immunol 2012; 129:787.</a></li><li><a class="nounderline abstract_t">Salzer E, Santos-Valente E, Keller B, et al. Protein Kinase C δ: a Gatekeeper of Immune Homeostasis. J Clin Immunol 2016; 36:631.</a></li><li><a class="nounderline abstract_t">Seidel MG, Hirschmugl T, Gamez-Diaz L, et al. Long-term remission after allogeneic hematopoietic stem cell transplantation in LPS-responsive beige-like anchor (LRBA) deficiency. J Allergy Clin Immunol 2015; 135:1384.</a></li><li><a class="nounderline abstract_t">Seidel MG. Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs). Hematology Am Soc Hematol Educ Program 2020; 2020:673.</a></li><li><a class="nounderline abstract_t">Egg D, Rump IC, Mitsuiki N, et al. Therapeutic options for CTLA-4 insufficiency. J Allergy Clin Immunol 2022; 149:736.</a></li><li><a class="nounderline abstract_t">Lankester AC, Albert MH, Booth C, et al. EBMT/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity. Bone Marrow Transplant 2021; 56:2052.</a></li><li><a class="nounderline abstract_t">Chan AY, Leiding JW, Liu X, et al. Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. Front Immunol 2020; 11:239.</a></li><li><a class="nounderline abstract_t">Fischer A. Gene therapy for inborn errors of immunity: past, present and future. Nat Rev Immunol 2023; 23:397.</a></li></ol></div><div id="topicVersionRevision">Topic 16362 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35748970" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32048120" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30776527" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28669558" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25999944" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Early-onset autoimmune disease as a manifestation of primary immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22052638" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : [Interdisciplinary AWMF guideline for the diagnostics of primary immunodeficiency].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28192146" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33895260" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33774840" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Autoimmune manifestations among 461 patients with monogenic inborn errors of immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22129055" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Immunodeficiency due to defects in store-operated calcium entry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24398331" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14752330" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: a model of immune dysregulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17666212" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Role of regulatory T cells and FOXP3 in human diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16243487" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : IPEX and FOXP3: clinical and research perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33186766" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Patterns of Immune Dysregulation in Primary Immunodeficiencies: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34797428" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The Immune Deficiency and Dysregulation Activity (IDDA2.1 'Kaleidoscope') Score and Other Clinical Measures in Inborn Errors of Immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25163701" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30940614" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35058929" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Autoimmune Cytopenias and Dysregulated Immunophenotype Act as Warning Signs of Inborn Errors of Immunity: Results From a Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33968040" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Primary Immunodeficiency in Children With Autoimmune Cytopenias: Retrospective 154-Patient Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32278790" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23233596" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The many faces of common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24817816" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21984609" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Immunological aspects of 22q11.2 deletion syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25329329" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25213377" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27114460" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30280610" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : STAT1 and STAT3 mutations: important lessons for clinical immunologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25359994" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25349174" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22608502" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26206937" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26768763" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30995531" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical, Immunologic, and Molecular Spectrum of Patients with LPS-Responsive Beige-Like Anchor Protein Deficiency: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31887391" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31945408" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24240290" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an evolving web of heritable autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12161590" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12522256" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Control of regulatory T cell development by the transcription factor Foxp3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29241729" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24167503" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : APECED: A Paradigm of Complex Interactions between Genetic Background and Susceptibility Factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4017274" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Autoimmune polyendocrinopathy--candidosis--ectodermal dystrophy (APECED): autosomal recessive inheritance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26141571" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22549091" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24746753" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Early-onset inflammatory bowel disease and common variable immunodeficiency-like disease caused by IL-21 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24746753" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Early-onset inflammatory bowel disease and common variable immunodeficiency-like disease caused by IL-21 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18319398" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Common variable immunodeficiency disorders: division into distinct clinical phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21119115" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20871412" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Recognizing gastrointestinal and hepatic manifestations of primary immunodeficiency diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26230867" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pathologic Findings in NEMO Deficiency: A Surgical and Autopsy Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30591564" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30026316" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23591608" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Autoimmunity in immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11929755" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Autoimmunity in human primary immunodeficiency diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26454316" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Autoimmune Disease in Primary Immunodeficiency: At the Crossroads of Anti-Infective Immunity and Self-Tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26768758" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The crossroads of autoimmunity and immunodeficiency: Lessons from polygenic traits and monogenic defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28755025" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Inflammatory Bowel Disease in Primary Immunodeficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28404814" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Nucleotide-binding oligomerization domain (NOD) signaling defects and cell death susceptibility cannot be uncoupled in X-linked inhibitor of apoptosis (XIAP)-driven inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31833544" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25843314" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Novel mutations in TNFRSF7/CD27: Clinical, immunologic, and genetic characterization of human CD27 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25339095" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Interleukin-2-inducible T-cell kinase (ITK) deficiency - clinical and molecular aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23043756" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Common variable immunodeficiency: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20832369" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical and immunological overlap between autoimmune lymphoproliferative syndrome and common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28011863" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28011864" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29434583" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : CD70 Deficiency due to a Novel Mutation in a Patient with Severe Chronic EBV Infection Presenting As a Periodic Fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22248322" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Familial and acquired hemophagocytic lymphohistiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24113228" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : X-linked lymphoproliferative syndromes and related autosomal recessive disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22801960" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22197273" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27541826" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Protein Kinase Cδ: a Gatekeeper of Immune Homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25539626" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Long-term remission after allogeneic hematopoietic stem cell transplantation in LPS-responsive beige-like anchor (LRBA) deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33275670" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34111452" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Therapeutic options for CTLA-4 insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34226669" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : EBMT/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32153572" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36434109" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Gene therapy for inborn errors of immunity: past, present and future.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
